MAPT and Alzheimer disease: In CSF, three core biomarkers have been validated as markers of AD neuropathology (Blennow et al., 2015): low levels of Aβ42 are indicative of brain amyloid pathology, elevated levels of phosphorylated tau (P-tau) signify tau pathology, and elevated levels of total tau reflect neurodegeneration (T-tau).